A systematic review of miRNAs as biomarkers for chemotherapy-induced cardiotoxicity in breast cancer patients reveals potentially clinically informative panels as well as key challenges in miRNA research

Table 2 Characterisation of cardiotoxicity in breast cancer patients during or after chemotherapy for each of the reviewed studies

	Reference	[28]	[29]	[30]	[31]	[32]	[33]	[34]	[35]
	Cohort size	45	179	363	56	56/32	34	40	72
	Treatment regime	NAC	ECD	ECD	DOX	EPI/DOX	DOX	AC	ECD-T
Assessment of Cardiotoxicity	Heart failure	1^a	1	0	0	0/0	0	0	0
	Acute coronary syndrome	0	0	0	0	0/0	0	0	1
	Fatal arrhythmias	0	9	0	0	0/0	0	0	0
	Decline of LVEF ≥10% of baseline or below 53%	17	9	19	10	0/0	4	20	12
	Elevated Troponin level	0	0	0	0	12/18	0	0	0

Key: EC-D = Epirubicin + Cyclophosphamide (4 cycles) followed by Docetaxel (4 cycles), DOX = Doxorubicin, EPI = Epirubicin, NAC = Cyclophosphamide + Epirubicin (4 cycles) followed by Paclitaxel (9 to 12 weeks), AC = Anthracycline chemotherapy (not specified), LVEF = Left ventricular ejection fraction
^aone patient was diagnosed with heart failure after the study period

ISSN: 2057-3804